(69 days)
Not Found
No
The device description details a DNA probe-based assay with a spectrophotometric or visual readout, relying on chemical reactions and optical density measurements. There is no mention of AI or ML in the device description, intended use, or performance studies.
No
The device is an in vitro diagnostic assay used for detecting genes related to vancomycin resistance, not for treating or preventing disease.
Yes
The Device Description explicitly states, "The Velogene™ Genomic Identification Assay for VRE (Vancomycin Resistant Enterococci) is an in vitro, DNA probe based, diagnostic device..."
No
The device description clearly outlines a physical kit containing reagents and microwells, indicating it is a hardware-based in vitro diagnostic device, not software-only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states "For the visual or spectrophotometric detection of the vanA and vanB genes in determining vancomycin resistance in enterococci isolated from culture." This describes a test performed on a biological sample (enterococci isolated from culture) to provide information about a medical condition (vancomycin resistance).
- Device Description: The description clearly states it is an "in vitro, DNA probe based, diagnostic device". "In vitro" means performed outside of a living organism, and "diagnostic device" indicates its purpose is to aid in diagnosis.
- Mechanism: The device works by detecting specific genes (vanA and vanB) in the isolated enterococci, which is a common method for in vitro diagnostic tests.
- Output: The output is a visual or spectrophotometric result indicating the presence or absence of these genes, which is then used to determine vancomycin resistance.
All of these characteristics align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Velogene™ Genomic Identification Assay for VRE is a qualitative DNA probe test which utilizes Cycling Probe™ Technology (CPT) to detect the vanA and vanB genes in isolated colonies of presumptively identified enterococci.
For the visual or spectrophotometric detection of the vanA and vanB genes in determining vancomycin resistance in enterococci isolated from culture.
Product codes
NIJ
Device Description
The Velogene™ Genomic Identification Assay for VRE (Vancomycin Resistant Enterococci) is an in vitro, DNA probe based, diagnostic device that utilizes Cycling Probe™ Technology (CPT) to generate a spectrophotometric or visual result. Results can be generated 90 minutes after primary isolation.
The Velogene™ Genomic Identification Assay for VRE (hereafter may be referred to as the Velogene™ assay) utilizes a fluorescein labeled, biotinylated DNA-RNA-DNA chimeric probe providing an RNase H cleavable linkage when bound to the complementary sequence of the van A or vanB gene. RNase H cleaves the RNA portion of the chimeric probe when it is hybridized to the target DNA. The uncleaved probe (vanA and vanB negative) is detected by binding of the fluoresceinated probe to a solid surface and attachment of an antifluorescein antibody conjugated with horseradish peroxidase, which converts a substrate to a colored end product. Cleavage of the probe (vanA or vanB positive) prevents binding of the probe-anti-fluorescein antibody enzyme complex, thus preventing formation of the colored end product. A vancomycin-resistant isolate (i.e. vanA or vanB gene is present) will produce a colorless result (or OD650 of ≤0.14). A vancomycin-sensitive isolate (i.e. vanA and vanB gene are absent) will produce a distinctly blue color (or OD650 of >0.14).
Each Velogene™ assay kit contains supplies sufficient to process 48 samples and consists of two separate reagent kits: a VRE Lysis/Cycle Kit and a VRE Microwell Detection Kit.
VRE Lysis/Cycle Kit
The Lysis/Cycle kit contains the reagents and components to:
- Lyse sample cells from an overnight culture of presumptively identified enterococci .
- Clarify the test solution .
- Complete the Cycling Probe™ Technology (CPT) process .
VRE Microwell Detection Kit
The detection kit contains the reagents and components to:
- Stop the CPT process ●
- Bind the biotinylated end of both cleaved and uncleaved probes and remove the . fluorescein labeled end of cleaved probes
- Complete the detection process .
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
A comparative study was performed at 3 geographically distributed U.S. sites using routinely submitted samples for microbiological identification. An agreement of 94.6% was obtained between the Velogene™ assay and the Vancomycin Screen Agar when 518 isolates of presumptively identified enterococci were tested (490/518).
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
MAY 0 1 2002
510(K) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92
Ko20576 The assigned 510(k) number is:
Submitter: ID Biomedical Corporation 1510 -- 800 West Pender Vancouver, British Columbia Canada V6C 2V6 Telephone: (604) 431-9314 Fax: (604) 431-93789 Establishment 3033040 Registration Number Contact Person: David N. Clary, Regulatory Affairs Associate ID Biomedical Corporation of Washington 19204 North Creek Parkwav Suite 100 Bothell, WA 98011 Telephone: (425) 482-2601, Ext. 424 Fax: (425) 482-2502 Date Prepared: February 20, 2002 Trade Name: Velogene™ Genomic Identification Assay for VRE Common Name: Manual genomic identity test II Device Class Classification Name: Manual antimicrobial susceptibility test system Special Controls No special controls have been issued for in vitro diagnostic devices under sections 513 and 514.
INTENDED USE
The Velogene™ Genomic Identification Assay for VRE is a qualitative DNA probe test which utilizes Cycling Probe™ Technology (CPT) to detect the vanA and vanB genes in isolated colonies of presumptively identified enterococci.
Confidential
1
DEVICE DESCRIPTION
The Velogene™ Genomic Identification Assay for VRE (Vancomycin Resistant Enterococci) is an in vitro, DNA probe based, diagnostic device that utilizes Cycling Probe™ Technology (CPT) to generate a spectrophotometric or visual result. Results can be generated 90 minutes after primary isolation.
The Velogene™ Genomic Identification Assay for VRE (hereafter may be referred to as the Velogene™ assay) utilizes a fluorescein labeled, biotinylated DNA-RNA-DNA chimeric probe providing an RNase H cleavable linkage when bound to the complementary sequence of the van A or vanB gene. RNase H cleaves the RNA portion of the chimeric probe when it is hybridized to the target DNA. The uncleaved probe (vanA and vanB negative) is detected by binding of the fluoresceinated probe to a solid surface and attachment of an antifluorescein antibody conjugated with horseradish peroxidase, which converts a substrate to a colored end product. Cleavage of the probe (vanA or vanB positive) prevents binding of the probe-anti-fluorescein antibody enzyme complex, thus preventing formation of the colored end product. A vancomycin-resistant isolate (i.e. vanA or vanB gene is present) will produce a colorless result (or OD650 of ≤0.14). A vancomycin-sensitive isolate (i.e. vanA and vanB gene are absent) will produce a distinctly blue color (or OD650 of >0.14).
Each Velogene™ assay kit contains supplies sufficient to process 48 samples and consists of two separate reagent kits: a VRE Lysis/Cycle Kit and a VRE Microwell Detection Kit.
VRE Lysis/Cycle Kit
The Lysis/Cycle kit contains the reagents and components to:
- Lyse sample cells from an overnight culture of presumptively identified enterococci .
- Clarify the test solution .
- Complete the Cycling Probe™ Technology (CPT) process .
VRE Microwell Detection Kit
The detection kit contains the reagents and components to:
- Stop the CPT process ●
- Bind the biotinylated end of both cleaved and uncleaved probes and remove the . fluorescein labeled end of cleaved probes
- Complete the detection process .
2
PREDICATE DEVICES
The predicate devices for ID Biomedical's Velogene™ Genomic Identification Assay for VRE kit are:
- . Brain Heart Infusion (BHI) Agar with 6 ug/mL vancomycin, #K941444, Remel
- . BHI Agar with 6 ug/mL vancomycin, #K964560, Hardy Diagnotics
Both are NCCLS approved tests for the detection of Vancomycin Resistant Enterococci (VRE).
SUMMARY OF SUBSTANTIAL EQUIVALENCE
Vancomvein Screen Agar
Vancomycin Screen Agar (BHI with 6 ug/mL Vancomycin) is a growth-based test that phenotypically identifies vancomycin resistance. Vancomycin screen agar is inoculated with a suspension of an overnight culture of enterococci and plates are examined for evidence of growth after a full 24 hours of incubation; growth indicates resistance to vancomycin.
Substantially equivalent characteristics:
- Both tests require isolates to be gram-positive, catalase-negative; .
- Both tests identify vancomycin resistance in enterococci due to the vanA or vanB . genes:
- Vancomycin screen agar and the Velogene™ assay identify vancomycin-resistant . enterococci.
Substantially equivalent clinical performance:
A comparative study was performed at 3 geographically distributed U.S. sites using routinely submitted samples for microbiological identification. An agreement of 94.6% was obtained between the Velogene™ assay and the Vancomycin Screen Agar when 518 isolates of presumptively identified enterococci were tested (490/518).
ID Biomedical Corporation believes that the Velogene™ Genomic Identification Assay for VRE is substantially equivalent in characteristics and clinical performance to the currently marketed Vancomycin Screen Agar (BHI with 6 ug/mL Vancomycin) for the identification of vancomycin-resistant enterococci when applied in accordance with the intended use and proposed labeling.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image is a black and white seal for the Department of Health & Human Services - USA. The seal is circular with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the top half of the circle. Inside the circle is an abstract image of what appears to be an eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 0-1 2002
Mr. David N. Clary Regulatory Affairs Associate ID Biomedical Corporation 19204 North Creek Parkway, Suite 100 Bothell, Washington 98011
K020576 Re:
Trade/Device Name: Velogene™ Genomic Identification Assay for VRE Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test System Regulatory Class: Class II Product Code: NIJ Dated: February 20, 2002 Received: February 21, 2002
Dear Mr. Clary:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at additionally 607.10 1011-11-10 101 - 10-11-2017 on the promotion and advertising of your device, (2017 59 + 12 6 + 1 1 2 c = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small monifacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrl/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Velogene™ Genomic Identification Assay for VRE
INDICATIONS FOR USE
Applicant: ID Biomedical Corporation, Vancouver, British Columbia, V6C 2V6 Canada
510(k) Number: K020576 .
Device Name: Velogene™ Genomic Identification Assay for VRE
Indications For Use:
For the visual or spectrophotometric detection of the vanA and vanB genes in determining vancomycin resistance in enterococci isolated from culture.
Freddie M. Poole
(Division Sign-Off) Division of Clinical Laboratory Devices
510(k) Number K020576
- for Presc
scriptive Use